MiniMed Group, Inc. (MMED): Results of Operations and Financial Condition
MiniMed Group, Inc. (MMED) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NEWS RELEASE FOR IMMEDIATE RELEASE MiniMed Delivers Strong Start to Fiscal Year 2027 with U.S. Growth Acceleration • Strong start to fiscal year with net sales of $843 million growing 17% as reported and 16% organic • U.S. net sales growth accelerated to 13%; continu
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise expectations for continued revenue expansion, supporting a bullish stance.
Market read
First‑time earnings disclosure with raised guidance creates a clear short‑term trading opportunity.
What to watch
Potential supply‑chain constraints for new sensor launches could temper growth.
MiniMed Delivers Strong Start to Fiscal Year 2027 with U.S. Growth Acceleration
Worldwide net sales grew 16.6% as reported and 15.8% organic, U.S. net sales growth accelerated to 13.1%, international net sales grew 18.1%, and the company raised fiscal 2027 organic revenue growth guidance to approximately 10.5% while reaffirming adjusted EBITDA margin guidance of approximately 16%.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Worldwide net salesGAAP | $843 million | – | 16.6% |
| Worldwide organic revenuenon-GAAP | $829 million | – | 15.8% |
| Cost of products soldGAAP | $378 million | – | – |
| Gross profitGAAP | $465 million | – | – |
| Research and development expenseGAAP | $115 million | – | – |
| Selling, general, and administrative expenseGAAP | $312 million | – | – |
| Certain litigation charges, netGAAP | $(2) million | – | – |
| Other operating expense (income), netGAAP | $36 million | – | – |
| Operating income (expense)GAAP | $5 million | – | – |
| Other non-operating (expense) income, netGAAP | — | – | – |
| Income (loss) before income taxesGAAP | $4 million | – | – |
| Income tax provisionGAAP | $4 million | – | – |
| Net income (loss)GAAP | $— | – | – |
| Net income attributable to noncontrolling interestsGAAP | — | – | – |
| Net income (loss) attributable to the CompanyGAAP | $— | – | – |
| Basic and diluted earnings (loss) per shareGAAP | $0.00 | – | – |
| Basic and diluted weighted average shares outstandingGAAP | 281.0 million | – | – |
| Worldwide New Pumps Soldother | ~34,000 | – | 7.7% |
| Worldwide CGM Attachment Rateother | 69% | ~100 bps | – |
| Favorable currency impact on net salesother | $14 million | – | – |
| Italian payback accrual benefit in Q1 FY26other | $7 million | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| U.S. net salesU.S. New Pumps Sold grew over 20% year over year, driven by MiniMed Flex™ and new sensor launches. | $240 million | – | 13.1% |
| International net salesDriven by Simplera™ capacity expansion and the launch of the Instinct sensor, made by Abbott. | $603 million | – | 18.1% |
| PumpsNot provided. | $144 million | – | 21.5% |
| ConsumablesNot provided. | $261 million | – | 13.8% |
| CGMNot provided. | $431 million | – | 19.9% |
| OtherPrimarily includes revenue generated from the sale of smart insulin pens and services. Q1 2026 included a $7 million benefit related to adjustments to the Company's Italian payback accruals. | $7 million | – | (57.1)% |
fiscal year 2027 ending April 30, 2027 outlook
- RevenueOrganic revenue growth of approximately 10.5%
- NoteOrganic revenue growth includes the approximate 1.0 to 1.5% benefit from the extra week in Q1 FY27.
- NoteAdjusted EBITDA margin of approximately 16%.
What drove it
- Worldwide net sales of $843 million grew 16.6% as reported and 15.8% organic.
- U.S. net sales of $240 million grew 13.1% as reported and organic.
- International net sales of $603 million grew 18.1% as reported and 16.9% organic.
- International growth was driven by Simplera™ capacity expansion and the launch of the Instinct sensor, made by Abbott.
- MiniMed Flex™ with Simplera™ launched in the U.S., and U.S. coverage expanded to Medicare and Medicare Advantage beneficiaries.
- MiniMed™ 780G system with Instinct and MiniMed Go™ with Instinct Go launched in Europe.
- MiniMed Fit™ patch pump was submitted to the U.S. FDA ahead of the Fall target, and MiniMed Flex™ received CE Mark well ahead of the calendar 2026 year end target.
Concerns
- The company stated that Q1 FY27 organic revenue growth included an approximate 4-6% benefit from the extra week resulting from its 52-53 week fiscal calendar.
- Other revenue was $7 million, down (57.1)% from $15 million, which included a $7 million Q1 FY26 benefit related to Italian payback accrual adjustments.
- Other operating expense (income), net was $36 million, compared with $(2) million in the prior-year period.
- GAAP net income attributable to the Company was $— and basic and diluted earnings per share was $0.00.
What to watch
- The full U.S. launch of MiniMed Fit™ is expected Summer 2027.
- The commercial launch of MiniMed Flex™ following CE Mark is expected in November.
- The Vivera™ fully-closed loop algorithm U.S. pivotal trial for T1 and T2 completed enrollment; the company remains on track for a second half calendar 2027 U.S. launch.
- The next-gen MiniMed extended wear sensor received U.S. IDE approval, with first pivotal-trial enrollment expected this Fall.
- Execution toward organic revenue growth of approximately 10.5% and adjusted EBITDA margin of approximately 16% for fiscal 2027.
Analysis
MiniMed opened FY27 with worldwide net sales of $843 million, up 16.6% as reported from $723 million, and organic revenue of $829 million, up 15.8% from $716 million. The company said the quarter included an approximate 4-6% benefit from the extra week in its 52-53 week fiscal calendar. Excluding that benefit, management said it generated low-double digit organic growth. The company raised its FY27 organic revenue growth outlook to approximately 10.5% from prior guidance of approximately 10%.
Geographically, the U.S. generated $240 million of net sales, up 13.1%, while international net sales were $603 million, up 18.1% as reported and 16.9% organic. U.S. New Pumps Sold grew over 20% year over year, with MiniMed Flex™ and new sensor launches identified as drivers. International growth reflected Simplera™ capacity expansion and the launch of the Instinct sensor, made by Abbott. Product revenue growth was led by Pumps at 21.5% and CGM at 19.9%, while Consumables increased 13.8%.
Gross profit was $465 million compared with $409 million in the prior-year quarter. Operating income was $5 million compared with an operating expense of $(13) million, while net income attributable to the Company was $— compared with a loss of $(19) million. Research and development expense was $115 million versus $125 million, whereas selling, general, and administrative expense increased to $312 million from $283 million. Other operating expense (income), net was $36 million versus $(2) million.
The company reported worldwide New Pumps Sold of approximately 34,000, up 7.7% year over year, and a worldwide CGM Attachment Rate of 69%, up approximately 100 basis points quarter over quarter. MiniMed Flex™ received CE Mark, MiniMed Fit™ was submitted to the U.S. FDA, Vivera™ pivotal-trial enrollment was completed, and the next-generation extended wear sensor received U.S. IDE approval. The guide also reaffirmed adjusted EBITDA margin of approximately 16%, while no GAAP profitability outlook was provided.
Management, verbatim
MiniMed delivered an excellent start to our fiscal year, with accelerating U.S. growth, continued double-digit international growth, and strong execution across our innovation pipeline.
Que Dallara, MiniMed Chief Executive Officer
The U.S. launch of MiniMed Flex™ is doing exactly what we designed it to do: bringing new patients into the MiniMed ecosystem, driving competitive conversions, and generating significant new account growth.
Que Dallara, MiniMed Chief Executive Officer
Not in the filing
stated, not guessed- Gross margin
- GAAP revenue guidance
- Forward operating-expense guidance
- Forward tax-rate guidance
- GAAP operating income guidance
- GAAP net income guidance
- GAAP EPS guidance
- Historical adjusted EBITDA and adjusted EBITDA margin
- Non-GAAP operating income, net income, and EPS
- Operating cash flow
- Free cash flow
- Cash and cash equivalents
- Debt
- Share repurchases
- Dividends
- Prior-quarter financial comparisons for revenue, expenses, profitability, and EPS
- Previous-release outlook for comparison with actual reported results
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
MiniMed Group, a Nasdaq‑listed diabetes technology company, filed an 8‑K reporting its Q1 FY27 results and updated FY guidance.
Ticker impact
MiniMed Group reported Q1 FY27 net sales of $843M, 16.6% growth and raised FY27 organic revenue guidance to ~10.5% and adjusted EBITDA margin to ~16% in its 8‑K filing.
Potential short‑term rally of 5‑10% as investors digest the beat and guidance lift.
First‑time disclosure of earnings and guidance, material revenue size, and clear growth trajectory provide a clear trading catalyst.
Market effects
Positive signal for the diabetes technology and broader med‑tech sector, may lift peers.
U.S. market may see modest gains in health‑care stocks.
International peers could benefit from demonstrated demand growth.
Counterpoint
If guidance is overly optimistic, the stock could face disappointment on later quarters.
Key entities
- ExecutiveQue Dallara
Chief Executive Officer of MiniMed Group who provided commentary on the results.
